Skip to content
School of Pharmacy

expertise: Comparative Effectiveness Research

(including: comparative effectiveness analysis)

Davene Wright

Biography

Davene Wright, PhD is a member of the faculty at the Harvard Pilgrim Health Care Institute and Harvard Medical School. Dr. Wright received her doctorate in Health Policy and Decision Sciences from Harvard University. Her research aims to improve the supply of and demand for efficient health care that can improve the management of pediatric chronic diseases, with a focus on childhood obesity. In her work, she utilizes conjoint analysis, economic evaluation, simulation modeling, and health services research methods. Dr. Wright’s work has been funded by NIH, the American Heart Association, and the American Diabetes Association.

Prior to transitioning to her role at Harvard, Dr. Wright was an Acting Assistant Professor of Pediatrics at the University of Washington and an Investigator within the Center for Child Health, Behavior and Development at Seattle Children’s Hospital.

David Veenstra

Education

  • PharmD, University of California, San Francisco
  • PhD in Pharmaceutical Chemistry, University of California, San Francisco

Research Interests

  • Precision medicine
  • Cost-effectiveness analysis
  • Managed care decision making

Courses Taught

  • Pharm 520: Introduction to Pharmacoeconomics
  • Pharm 542: Managed Care Pharmacy

Biography

Dr. Veenstra is a Professor in the Comparative Health Outcomes, Policy & Economics (CHOICE) Institute in the Department of Pharmacy at the University of Washington.

Dr. Veenstra’s primary research interests are the clinical, economic, and policy implications of precision medicine. His major research projects include evaluation of the cost effectiveness of population-level genomic screening, and evidence thresholds and preferences for precision medicine.

Dr. Veenstra’s research has been funded through grants from the National Human Genome Research Institute, Centers for Disease Control, and the National Cancer Institute.
He also has worked extensively with organizations such as the Academy of Managed Care Pharmacy (AMCP) and the Institute for Clinical and Economic Review (ICER) to further the practical application of cost-effectiveness analysis in managed care decision making.

Dr. Veenstra teaches courses in health economics and managed care and is an author of five book chapters and 240 peer-reviewed publications.

Recent Publications

  1. Guzauskas GF, Garbett S, Zhou Z, Schildcrout JS, Graves JA, Williams MS, Hao J, Jones LK, Spencer SJ, Jiang S, Veenstra DL*, Peterson JF*. Population Genomic Screening for Three Common Hereditary Conditions: A Cost-Effectiveness Analysis. Ann Intern Med. 2023 May;176(5):585-595. PMID: 37155986
  2. Lee W, Dayer V, Jiao B, Carlson JJ, Devine B, Veenstra DL. Use of real-world evidence in economic assessments of pharmaceuticals in the United States. J Manag Care Spec Pharm. 2021 Jan;27(1):5-14. PMID: 33377439
  3. Guzauskas GF, Basu A, Veenstra DL. Are there different evidence thresholds for genomic vs. clinical precision medicine? A VOI-based framework applied to antiplatelet drug therapy. Value in Health, 2019.
  4. Dhanda DS, Veenstra DL, Regier DA, Basu A, Carlson JJ. Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment. J Manag Care Spec Pharm. 2020 Apr;26(4):529-537. PMID: 32223606
  5. Henderson LM, Robinson RF, Ray L, Li T, Dillard DA, Schilling BD, Mosley M, Janssen PL, Fohner AE, Rettie AE, Thummel KE, Thornton TA, Veenstra DL. VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. Clin Transl Sci. 2019 Mar 1. PMID: 30821933.

Sean D. Sullivan

Positions

Professor of Pharmacy, School of Pharmacy, Professor of Health Services, School of Public Health, University of Washington

Education

  • BSc.Pharm 1983 Oregon State University, College of Pharmacy
  • M.Sc. 1986 University of Texas, College of Pharmacy (Administrative and Economic Sciences)
  • Ph.D. 1992 University of California, Berkeley (Health Economics and Policy)

Research Interests

  • Pharmaceutical policy
  • Economic evaluation of pharmaceuticals
  • Global health technology assessment
  • Medical decision making

Courses Taught

  • HECON 530 – Practice of Healthcare Technology Assessment in a Global Environment
  • HEOR 545 – Topics in Pharmaceutical Policy
  • PHRMCY 515 – Population Health and Pharmacy Management

Biography

Sean D. Sullivan, BScPharm, MSc, PhD, is a Professor, School of Pharmacy and Visiting Professor, London School of Economics and Political Science. He holds a joint appointment as Professor of Health Services, School of Public Health. Dr. Sullivan was Dean of the School of Pharmacy from 2014 to 2022.

He completed training in pharmacy at Oregon State University in 1983, obtained a master’s degree at the University of Texas in 1986 and a PhD in health economics and policy at the University of California, Berkeley in 1992.

Dr. Sullivan has authored more than 450 articles, book chapters and reports. In many of these, he has assessed the evidence and applications of medical technology in relation to coverage and reimbursement decisions. His research interests include health technology assessment, medical decision-making, and economic evaluation of medical technology, including pharmaceuticals. He is past president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and past chair of the Academy of Managed Care Pharmacy (AMCP) Executive Committee of the Format for Formulary Submissions – the United States evidence-based guidelines for formulary decision making.

Dr. Sullivan was a member of the Medicare Evidence Development and Coverage Advisory Committee, Chair of the Regence Blue Shield and Premera Blue Cross P/T Committee, and Chair of the Premera Blue Cross Value Assessment Committee. He was awarded the 2014 Stephen G. Avey Lifetime Achievement Award from the Academy of Managed Care Pharmacy (AMCP), and the 2015 APhA Academy of Pharmaceutical Research Sciences (APRS) Research Achievement Award. In 2020, he was elected to the National Academy of Medicine and in 2022 was elected Fellow, American Association for the Advancement of Science (AAAS).

Selected Publications

  • Cousin EM, Sullivan SD, Gabriel N, Hansen RN, Hernandez I. Drugs Anticipated to Be Selected for Medicare Price Negotiation in 2025 for Implementation in 2027. J Manag Care Spec 2024 Nov;30(11):1203-1210. doi: 10.18553/jmcp.2024.24167.
  • Sullivan SD, Wouters OJ, Cousin EM, Kirihennedige A, Hernandez I. Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform Medicare Drug Price Negotiation. Value in Health 2024 Oct;27(10):1348-1357. doi: 10.1016/j.jval.2024.08.001.
  • Hernandez I, Wouters OJ, Cousin EM, Kirihennedige A, Sullivan SD. Interpreting the First Round of Maximum Fair Prices Negotiated by Medicare for Drugs. Health Affairs Forefront 2024 September 3, 2024 10.1377/forefront.20240830.863408
  • Wouters OJ, Sullivan SD, Cousin EM, Gabriel N, Papanicolas I, Hernandez I. Drug Prices Negotiated by Medicare vs US Net Prices and Prices in Other Countries. JAMA 2025 Jan 7;333(1):85-87. doi: 10.1001/jama.2024.22582.
  • Sullivan SD, Chaturvedi S, Gautam P, Arnaud A. Cost effectiveness of caplacizumab in Immune thrombotic thrombocytopenic purpura in the US. J Manag Care Spec 2024 Dec 23:1-12. doi: 10.18553/jmcp.2025.24271.
  • Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD. Overpayment for Generic Drugs under Medicare Part D: Consequences on Patient Out-of-Pocket Costs. JAMA Health Forum 2025; 6(2):e250012. doi:10.1001/jamahealthforum.2025.0012
  • Hernandez I, Gabriel N, Japinga M, Pathak Y, Hansen RN, Sullivan SD, Fendrick AM. Projected Out of Pocket Savings of the Medicare Part D Two Dollar Drug List. JAMA 2025 March 24 On-line doi:10.1001/jama.2025.2028
  • Jofre-Bonet M, McGuire A, Dayer V, Roth JA, Sullivan SD. The Price Effects of Biosimilars in the US. Value in Health 2025. https://doi.org/10.1016/j.jval.2025.02.008
  • Sullivan SD, Grueger J, Sullivan AP, Ramsey SD. The Consequences of Pharmaceutical Tariffs in the US. JMCP In press, May, 2025
  • Sun, L, Veenstra DL, Brufsky A, Pluard T, Sandin R, Stergiopoulos S, Liu J, Williams T, Sullivan SD. First Line CDK4/6 Inhibitors in Combination with Aromatase Inhibitors for HR+/HER2- Metastatic Breast Cancer: Real World Outcomes and Costs in a Medicare Population. J Manag Care Spec Pharm in press, 2025

Ryan Hansen

Education

  • PhD in Pharmaceutical Outcomes Research and Policy, UW
  • PharmD, UW
  • Bachelor of Arts in Chemistry and Philosophy, Carroll College

Research Interests

  • Cost-effectiveness modeling
  • Comparative effectiveness research
  • Medication safety

Courses Taught

  • PHRMCY 512: Fundamentals of US Health Care, Pharmacy Safety and Law
  • HEOR 505: Managed Care Pharmacy
  • HEOR 530: Economic Evaluation in Health and Medicine
  • HEOR 532: Advanced Methods in Economic Evaluation
  • HEOR 545: Pharmaceutical and Medical Policy Evaluation
  • HEOR 597: Graduate Seminar

Biography
Dr. Hansen is Professor of Pharmacy and Chair of the Department of Pharmacy. His primary research interests focus on the comparative safety of prescription medications, health technology assessment, and health care system efficiency. He received his Bachelor of Arts from Carroll College, and his Doctor of Pharmacy and Doctor of Philosophy from the University of Washington.

Selected Recent Publications

Elsisi, Z, Canestaro WJ, Steuten L, Hansen RN. Applying Early Health Technology Assessment (e-HTA) to Inform Investment in Novel Health Technologies in the US. International Journal of Technology Assessment in Health Care 2025. In Press.

Gold LS, Heagerty PJ, Hansen RN, Friedly JL, Johnston SK, Deyo RA, Curatolo M, Turner JA, Rundell SD, Wysham K, Jarvik JG, Suri P. Adverse respiratory events during treatment with gabapentin and opioids among older adults with spine-related conditions: a propensity-matched cohort study in the US Medicare population. Spine 2025. In Press.

Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD, Fendrick AM. Projected Out of Pocket Savings of the Medicare Part D Two Dollar Drug List Model. JAMA 2025. In Press.

Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD. Overpayment for Generic Drugs under Medicare Part D: Consequences on Patient Out-of-Pocket Costs. JAMA Health Forum 2025;6(2):e250012.

Gold LS, Heagerty PJ, Hansen RN, Friedly JL, Johnston SK, Deyo RA, Curatolo M, Turner JA, Rundell SD, Wysham K, Jarvik JG, Suri P. Mortality after concurrent treatment with gabapentin and opioids in older adults with spine diagnoses. PAIN 2024. In Press.

Cousin EM, Sullivan SD, Hansen RN, Gabriel N, Kirihennedige AS, Hernandez I. Drugs Anticipated to Be Selected for Medicare Price Negotiation in 2025 for Implementation in 2027. Journal of Managed Care & Specialty Pharmacy 2024;30(11): 1203-1210.

Tran J, Mishra A, Zimmerman M, Hansen RN. Bridging PrEP Access Gaps: Mapping Geospatial Accessibility Across the US and Leveraging Community Pharmacies for Expansion. Journal of the American Pharmacists Association 2024. In Press.

Hernandez I, Sullivan SD, Hansen RN, Fendrick AM. Cheaper Isn’t Always Better: Drug Shortages in the U.S. and A Value-Based Solution to Alleviate Them. Journal of Managed Care & Specialty Pharmacy 2024;30(7):719-26.

Tsui JI, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, Hunt RR, Sandvold R, Taber K, Kubiniec RH, Scott JD, Hansen RN, Stekler JD, Austin EJ, Williams EC, Glick SN. Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug and Alcohol Dependence Reports 2024. In Press.

Green TC, Silcox J, Bolivar D, Gray M, Floyd AS, Irwin AN, Hansen RN, Hartung D, Bratberg J. Pharmacy staff-reported adaptations to naloxone provision and over the counter (OTC) syringe sales during the COVID-19 pandemic: experiences across multiple states and two pharmacy chains. Journal of the American Pharmacists Association 2024;64(1):71-78.

Hernandez I, Gabriel N, Kaltenboeck A, Boccuti C, Hansen RN, Sullivan SD. Reimbursement to Pharmacies for Generic Drugs by Medicare Part D Sponsors. JAMA 2023;330(24):2390-92.

Tabah A, Gold LS, Marcum ZA, Hansen RN. Antidepressants and the Risk of Fall-related Injury in Older Adults with Incident Depression in the United States: A Comparative Safety Analysis. Pharmacoepidemiology 2023. In Press.

Bacci, JL, Marcum ZA, Rodriguez P, Hansen RN, Bansal A, Pfund T, Kim JJ, Odegard P. Community pharmacist intervention to optimize statin adherence in diabetes care: The GuIDE-S study. Journal of the American Pharmacists Association 2023;63(3):946-51.

Jiao B, Fredricks DN, Srinivasan S, Hansen RN. Economic Evaluation of a Point-of-Care Test for Bacterial Vaginosis among Women with Vaginal Symptoms. Sexually Transmitted Diseases 2023;50(5):310-6.

Jiang S, Seslar SP, Sloan LA, Hansen RN. Healthcare Resource Utilization and Costs Associated with Atrial Fibrillation and Rural-urban Disparities. Journal of Managed Care and Specialty Pharmacy 2022;28(11):1321-30.

Nitkin D, Lin GA, Campbell JC, Hansen RN, Brouwer E, Chen Y, Herron-Smith S, Agboola F, Pearson SD. The Effectiveness and Value of Tirzepatide for Type 2 Diabetes Mellitus. Journal of Managed Care and Specialty Pharmacy 2022;28(6):680-4.

Ko GC, Hansen RN, Carlson JJ. Comparing Costs and Healthcare Resource Utilization Between nmHSPC and mHSPC Patients: A Retrospective Claims Analysis. Journal of Managed Care and Specialty Pharmacy 2022;28(3):287-95.

Agboola F, Atlas SJ, Brouwer E, Carlson JJ, Hansen RN, Herron-Smith S, Nhan E, Rind DM, Pearson SD. JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis: Effectiveness and Value. Journal of Managed Care and Specialty Pharmacy 2022;28(1):108-14.

Bratburg J, Irwin A, Hartung D, Floyd A, Bogis J, Hansen RN, Green T. Study Protocol for the Respond to Prevent Study: A multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies. Substance Abuse 2022;41(3):901-5.

Hansen RN, Saour B, Serafini B, Hannaford B, Kim L, Kohno T, James R, Monsky W, Seslar S. Opportunities and Barriers to Rural Telerobotic Surgical Healthcare in 2021: Report and Research Agenda from a Stakeholder Workshop. Telemedicine and e-Health 2022;28(7):1050-7.

Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. ‘Treat my whole person, not just my condition’: Qualitative explorations of Hepatitis C care delivery preferences among people who inject drugs. Addiction Science and Clinical Practice 2021;16 (1):52.

Pocobelli G, Akosile MA, Hansen RN, Eavey J, Wellman RD, Johnson RL, Carls G, Bron M, Dublin S. Obstructive Sleep Apnea and Risk of Motor Vehicle Accident. Sleep Medicine 2021;85:196-203.

Banta-Green CJ, Hansen RN, Ossiander EM, Wasserman CR, Merrill JO. Buprenorphine utilization among all Washington State residents based upon prescription monitoring program data- Characteristics associated with two measures of retention and patterns of care over time. Journal of Substance Abuse Treatment 2021;127:108446 epub.

Brouwer E, Yeung K, Barthold D, Hansen RN. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in one mid-size integrated health system. Journal of Managed Care and Specialty Pharmacy 2021;27(6):732-42.

Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN. Cost-Effectiveness of Oral Semaglutide Added to Current Antihyperglycemic Treatment for Type 2 Diabetes. Journal of Managed Care and Specialty Pharmacy 2021;27(4):455-68.

Landaas EJ, Baird GS, Hansen RN, Flum DR, Sullivan SD. Integrating Formal Technology Assessment into an Integrated Healthcare Delivery System: Smart Innovation. International Journal of Health Technology Assessment in Health Care 2020;36(1):58-63.

Tice JA, Guzauskas GF, Hansen RN, Herron-Smith S, Segel C, Walsh JME, Pearson SD. The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy. Journal of Managed Care and Specialty Pharmacy 2020;26(5):620-3.

Gold LS, Nazareth TA, Yu T, Fry KR, Mahler N, Rava A, Waltrip RW, Hansen RN. Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms. Pediatric Health, Medicine and Therapeutics 2019;10:195-207.

Gold LS, Patrick DL, Hansen RN, Goss CH, Kessler L. Correspondence between Lung Function and Symptom Measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). Journal of Cystic Fibrosis 2019;18(6):886-93.

Bacci JL, Hansen RN, Ree C, Reynolds MJ, Stergachis A, Odegard PS. The effects of vaccination forecasts and value-based payment on adult immunizations by community pharmacists. Vaccine 2019;37(1):152-9.

Beth Devine

Education

  • MSc, Medical Statistics and Health Data Science, University of Bristol
  • Post-doctoral Fellowship, The CHOICE Institute, UW and Roche Global Pharma Business
  • PhD, Health Services Research, UW
  • MBA, University of San Francisco
  • PharmD, University of the Pacific
  • Clinical Pharmacy Residency, Palo Alto VA Medical Center

Research Interests

  • Evidence synthesis; systematic reviews, meta-analysis, network meta-analysis using Bayesian and frequentist methods.
  • Precision medicine: pharmacogenomics; genomic risk for hereditary cancers.
  • Health technology assessment and outcomes research including preference-based methods, discrete choice experiments and multi-criteria decision analysis.
  • Comparative effectiveness research in the context of clinical informatics.
  • Real world evidence of costs and outcomes.
  • Medication safety.

Biography

Beth Devine is Professor Emerita at The CHOICE Institute, School of Pharmacy Prior to becoming emerita, she held adjunct professorships in the Department of Health-Systems and Population Health, School of Public Health and the Department of Biomedical Informatics, School of Medicine.

She also held the Shirley and Herb Bridge Endowed Professor for Women in Pharmacy (2021-2023). She is currently a Visiting Professor at the University of Bristol, UK (2024-2026). She was a Fulbright US Scholar to the University of Murcia, Spain (2021-2022) and an Honorary Professor there (2022-2023).

She is currently president-elect of ISPOR – The Professional Society for Health Economics and Outcomes Research (2025-2026), was a member of the Board of Directors of ISPOR (2021-2024) and is an Associate Editor for the ISPOR journal Value in Health (2021-2029). She served on the ISPOR Task Force that developed guidelines to conduct network meta-analyses (2009-2011) and is currently co-chairing the ISPOR Task Force to update to these guidelines (2026). From 2014-2025 she served as an Assistant Director of the AHRQ-funded Pacific Northwest Evidence-based Practice Center. In 2013, she was elected as a member of the Society for Research Synthesis Methodology.

Prior to joining the faculty at the UW, Dr. Devine was an advanced practice (prescribing) clinical pharmacist and led the Pharmacy & Therapeutics Committee at the University of California San Francisco. where she served a term as president of the California Society of Health-System Pharmacists, earning their Lifetime Achievement Award for her leadership role in advancing the scope of practice for California pharmacists through legislation (1994).

Courses Taught

  • HEOR DS 510: Data Science in Health Economics and Outcomes Research
  • HECON 530 – Health Technology Assessment in a Global Environment
  • HEOR 531/HSERV 584 – Assessing Outcomes in Health & Medicine
  • PHRMCY 514 – Design and Analysis of Medical Studies

Selected Peer-Reviewed Publications

MyNCBI Bibliography
https://www.ncbi.nlm.nih.gov/myncbi/emily.devine.1/bibliography/public/

Google Scholar Profile: (n = 336; citations: 11294; h-index = 43, i10-index = 128)
https://scholar.google.com/citations?user=Wor4Qv0AAAAJ&hl=en

Anirban Basu

Education

  • PhD, Public Policy (Health Economics), University of Chicago, 2004
  • MS, Biostatistics, UNC-Chapel Hill, 1999
  • MS, Industrial Pharmacy, University of Toledo, 1997
  • BS, Pharmaceutical Technology, Jadavpur University India

Courses Taught

  • Welfare Economics foundations for cost-effectiveness analysis (HSERV 583, ’11 & ‘12) – 1.5 hour sessions
  • Understanding the role of uncertainty in decision models (HSERV 583, ’13 & ‘14) – 1.5 hour sessions
  • Quantitative methods for valuing information in health care (HSERV 584, ‘11) – 1.5 hour sessions
  • Introduction to comparative effectiveness methods (HSERV 523, ’11; HSERV 513 & HSERV 592, ’12) – 1.5 hour sessions
  • Instrumental variable methods (HSERV 523, ‘11) – 1.5 hour session
  • Financing healthcare (HuBio 555, ’13, ‘14) – 1.5 hour session to 250 2nd year medical students
  • Quantile regression methods (HSERV 525, ’11, HSERV 523, ‘12) – 1.5 hour sessions
  • Variations in healthcare spending: Observations & Implications (PHARM 568, ’14 -‘16) – 1.5 hour sessions
  • Causal inference in observational studies (HSERV 525), Spring 2013 -2019- Ten 3 hour sessions.

Research Interests

  • comparative and cost-effectiveness analyses
  • causal inference methods
  • program evaluation, and outcomes research

Biography

Anirban Basu, PhD, MS, is a health economist and a statistician who specializes in research on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research. He directs The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington, Seattle, with appointments in the departments of Pharmacy, Health Services, and Economics at the university. He is a Faculty Research Fellow at the National Bureau of Economic Research, and a Fellow of the American Statistical Association. He was one of the panelists for the Second Panel on the Cost-Effectiveness Analysis in Health and Medicine. He studies heterogeneity in clinical and economic outcomes, micro behavior with respect to heterogeneous information, and the value of individualized care. He teaches topics in health economics, decision analysis, cost-effectiveness analysis, and health services research methods. He received his PhD in Public Policy (Health Economics Specialization) from The University of Chicago and an MS in Biostatistics from the University of North Carolina at Chapel Hill. http://faculty.washington.edu/basua/

Selected Publications

https://scholar.google.com/citations?user=AR72duAAAAAJ&hl=en

Josh Carlson

Education

  • PhD in Public Health Genetics, University of Washington
  • Master of Public Health in Public Health Genetics, University of Washington

Research Interests

  • Economic Evaluation of Healthcare Interventions
  • Comparative Effectiveness Research
  • Precision Medicine

Courses Taught

  • HEOR 530
  • PHRMCY 515

Biography

Dr. Carlson is a Professor in the The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute in the School of Pharmacy at the University of Washington. He graduated with his PhD from the Institute for Public Health Genetics in the School of Public Health and Community Medicine at the University of Washington in 2007 and conducted his postdoctoral training in health economics and outcomes research in the Pharmaceutical Outcomes Research and Policy Program (now the CHOICE Institute) at the University of Washington from 2007-2009. He was awarded the ISPOR Bernie J. O’Brien new investigator award in 2014.

Dr. Carlson’s research seeks to inform healthcare decision making using economic modeling, evidence synthesis, preference assessment, and health policy evaluation. This work spans many diseases, topics, and methodologies, but specific focus areas include economic analysis, precision medicine, and performance-based risk sharing arrangements. He has diverse formal training in decision modeling, discrete choice experiments, comparative effectiveness, outcomes research, and public health genetics.

Aasthaa Bansal

Dr. Bansal is an Associate Professor and the Edwin S.H. Leong Chair in Data Science for Child Health at the Institute of Health Policy, Management and Evaluation, University of Toronto and The Hospital for Sick Children. Prior to joining the University of Toronto in September 2025, Dr. Bansal served on the faculty at The CHOICE Institute and Department of Pharmacy for 12 years. Dr. Bansal’s research focuses on sequential decision-making using longitudinal data, prediction modeling, decision theoretic methods including value of information analysis, and comparative effectiveness and outcomes research using large healthcare claims databases and EHR data. She is the PI of a study to develop methods for cost-effective personalized risk-adaptive surveillance in cancer.

Education

  • Ph.D. Biostatistics, University of Washington, Seattle, WA
  • M.S. Biostatistics, University of Washington, Seattle, WA
  • B.Math. Honors Computer Science: Bioinformatics Option, University of Waterloo, Waterloo, Ontario

Courses Taught

  • BIOST 512: Medical Biometry II
  • HEOR 552 Application of Machine Learning in Health Economics and Outcomes Research

Research Interests

  • Clinical decision sciences
  • Development and evaluation of prediction models
  • Comparative effectiveness and outcomes research

Selected Publications

https://www.ncbi.nlm.nih.gov/myncbi/aasthaa.bansal.1/bibliography/public/